At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 38 enrolled
Drug / intervention
AGI-134drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/IIa, Multicentre, Two Parts, Open-Label Study Designed to Evaluate the Safety and Tolerability of Escalating Doses of AGI-134 in Unresectable/Metastatic Solid Tumours
In Brief
A Phase 2 clinical trial evaluating AGI-134 for Superficial, Palpable, Unresectable/Metastatic Solid Tumour. Completed, enrolled 38 participants across 14 sites in 3 countries.
Detailed Summary
This study will evaluate if AGI-134 given alone is safe and tolerate in treating patients with unresectable/metastatic solid tumours.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesIsrael, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJul 2018
Enrollment StartNov 2018
Primary CompletionDec 2023
TodayJul 2026
First PostedJul 20, 2018
Enrollment StartNov 30, 2018
Primary CompletionDec 31, 2023
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 8.0 years ago
Interventions
AGI-134drug
AGI-134 via IT injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.